Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findings

OBJECTIVE: Maraviroc, a chemokine co-receptor type 5 (CCR5) antagonist, has demonstrated comparable efficacy and safety to efavirenz, each in combination with zidovudine/lamivudine, over 96 weeks in the Maraviroc vs. Efavirenz Regimens as Initial Therapy (MERIT) study. Here we report 5-year findings...

Descripción completa

Detalles Bibliográficos
Autores principales: Cooper, David A., Heera, Jayvant, Ive, Prudence, Botes, Mariette, Dejesus, Edwin, Burnside, Robert, Clumeck, Nathan, Walmsley, Sharon, Lazzarin, Adriano, Mukwaya, Geoffrey, Saag, Michael, van Der Ryst, Elna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2014
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3940293/
https://www.ncbi.nlm.nih.gov/pubmed/24983542
http://dx.doi.org/10.1097/QAD.0000000000000131

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3940293/
https://www.ncbi.nlm.nih.gov/pubmed/24983542
http://dx.doi.org/10.1097/QAD.0000000000000131

Ejemplares similares